Vincent Picozzi, MD, discusses treatment for patients with pancreatic cancer who undergo surgery. Overall, the landscape lacks data on how to optimally sequence chemotherapy in patients with resectable disease.
Vincent Picozzi, MD, director of the Pancreas Center of Excellence, Digestive Disease Institute, Virginia Mason Medical Center, discusses treatment for patients with pancreatic cancer who undergo surgery. Overall, the landscape lacks data on how to optimally sequence chemotherapy in patients with resectable disease.
In general, Picozzi says these patients are treated according to a specific predesignated treatment protocol. The most common treatment for these patients is to first receive chemotherapy, then chemoradiation followed by surgery.
Picozzi notes that there is little to no chemotherapy administered after surgery. Some studies call the role of chemoradiation preoperatively into question. The whole way that different therapies are integrated and sequenced is now being reexamined at this time.
At the 2020 Gastrointestinal Cancers Symposium, Picozzi presented an analysis aimed to address this challenge in pancreatic cancer. The goal of the study is to identify patterns of recurrence to find patients who require subsequent therapy following surgery.
<< View more information on this analysis in pancreatic cancer
PD-L1 Status Shapes Choice of Using Nivolumab in Upper GI Cancer
March 27th 2024During a Case-Based Roundtable® event, David Zhen, MD, discussed the issue of treating patients with upper gastrointestinal cancer with a PD-L1 composite positive score less than 5 with nivolumab vs chemotherapy alone, in the first article of a 2-part series.
Read More
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More